Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › siltuximab

siltuximab

2 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials of siltuximab

9 trials tracked of siltuximab: 1 in phase 3 or 4 and 1 with published results. The most-cited published study has 163 citations.

9Trials tracked
1Phase 3 & 4
0Recruiting
1With published results
Phase distribution
Phase 3 1 Phase 2 7 Phase 1 1
  1. Phase 3 Treatment of COVID-19 Patients With Anti-interleukin Drugs Completed · 163 cited
  2. Phase 2 Lenalidomide/Bortezomib/Dexamethasone & CNTO 328 in Transplant Eligible Newly Diagnosed Multiple Myeloma (MM) Completed
  3. Phase 2 A Study to Evaluate the Efficacy and Safety of CNTO328 Plus Best Supportive Care in Multicentric Castleman's Disease Completed
  4. Phase 2 Siltuximab and Spartalizumab in Patients With Metastatic Pancreatic Cancer Completed
  5. Phase 2 A Study of Siltuximab (Anti- IL 6 Monoclonal Antibody) in Patients With High-risk Smoldering Multiple Myeloma Completed
  6. Phase 2 Study to Evaluate the Role of Siltuximab in Treatment of Cytokine Release Syndrome (CRS) and Immune Effector Cell Associated Neurotoxicity (ICANS) Related to CAR-T Cell Therapy Completed
Show 3 more trials
  1. Phase 2 A Study to Evaluate the Safety of Long-term Treatment With Siltuximab in Patients With Multicentric Castleman's Disease Completed
  2. Phase 2 A Study of the Safety and Efficacy of CNTO 328 and Bortezomib to Bortezomib Alone in Patients With Relapsed or Refractory Multiple Myeloma Completed
  3. Phase 1 Modulation of STAT3 Signaling With Siltuximab in Type 1 Diabetes Completed

Showing the 9 most-cited and recently-updated of 9 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Early daratumumab or immunomodulatory agents in high-risk smoldering multiple myeloma show uncertain benefits versus observation
Allergy & Immunology Sys. Review
Early daratumumab or immunomodulatory agents in high-risk smoldering multiple myeloma show uncertain benefits versus observation Early Drug May Delay Multiple Myeloma
This systematic review evaluated early intervention with monoclonal antibodies, immunomodulatory agents, or alkylating agents versus observa…
Imagine waking up with a headache. You take a pill, and the pain goes away.
Cochrane Apr 10, 2026
Siltuximab shows partial response in two iMCD-IPL cases with xanthelasma; skin lesions unchanged
Hematology Sys. Review
Siltuximab shows partial response in two iMCD-IPL cases with xanthelasma; skin lesions unchanged Two patients with rare Castleman disease had xanthelasma that did not improve with treatment
A case report describes two Asian women in their 5th decade with idiopathic plasmacytic lymphadenopathy subtype of idiopathic multicentric C…
Two women with rare Castleman disease saw their skin inflammation improve but stubborn yellow eyelid patches stayed despite treatment.
Frontiers Apr 1, 2026